Heartware went cheaply - probably chickened out in a tough market, i.e. they knew that without substantial backing THEY might not make it to market. I suggest the transfer of domicile to the US was part of their strategy, i.e. funding might be easier there and/or takeover offers would then be more of a possibility!
VCR know how tough cracking their intended market is and the economic conditions over the last 18 months have obviously taken their toll on VCR chances - had circumstances been different they may very well have had the funding needed to complete FDA approval and get to market, IMO. Then a whole bunch of (negative ramping) posters would have been crowing "I told you so"!!!
BTW, would not be surprised to find that VCR was approached by Thoratic and VCR would not play ball - although we will probably never know one way or another...
VCR
ventracor limited
